ATE370142T1 - Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3 - Google Patents

Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3

Info

Publication number
ATE370142T1
ATE370142T1 AT04766189T AT04766189T ATE370142T1 AT E370142 T1 ATE370142 T1 AT E370142T1 AT 04766189 T AT04766189 T AT 04766189T AT 04766189 T AT04766189 T AT 04766189T AT E370142 T1 ATE370142 T1 AT E370142T1
Authority
AT
Austria
Prior art keywords
triazolopyrimidene
inhibitors
derivatives
glycogen synthase
synthase kinase
Prior art date
Application number
AT04766189T
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Christopher John Love
Ludwig Paul Cooymans
Nele Vandermaesen
Peter J J A Buijnsters
Marc Willems
Werner C J Embrechts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE370142T1 publication Critical patent/ATE370142T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT04766189T 2003-07-16 2004-07-12 Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3 ATE370142T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP0350310 2003-07-16

Publications (1)

Publication Number Publication Date
ATE370142T1 true ATE370142T1 (de) 2007-09-15

Family

ID=34112425

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04766189T ATE370142T1 (de) 2003-07-16 2004-07-12 Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3

Country Status (26)

Country Link
US (2) US7560458B2 (de)
EP (1) EP1658292B1 (de)
JP (1) JP2009514782A (de)
KR (1) KR20060120393A (de)
CN (1) CN100404536C (de)
AP (1) AP2006003486A0 (de)
AR (1) AR045698A1 (de)
AT (1) ATE370142T1 (de)
AU (1) AU2004260738B2 (de)
BR (1) BRPI0412596A (de)
CA (1) CA2531333A1 (de)
DE (1) DE602004008303T2 (de)
DK (1) DK1658292T3 (de)
EA (1) EA010109B1 (de)
ES (1) ES2290754T3 (de)
IL (1) IL173139A (de)
JO (1) JO2460B1 (de)
MX (1) MXPA06000540A (de)
NO (1) NO20060678L (de)
NZ (1) NZ545058A (de)
PA (1) PA8607001A1 (de)
PL (1) PL1658292T3 (de)
PT (1) PT1658292E (de)
TW (1) TW200524935A (de)
WO (1) WO2005012307A1 (de)
ZA (1) ZA200600385B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE451104T1 (de) 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
US7138402B2 (en) * 2003-09-18 2006-11-21 Conforma Therapeutics Corporation Pyrrolopyrimidines and related analogs as HSP90-inhibitors
AU2004260738B2 (en) * 2003-07-16 2009-07-16 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
CN1849318B (zh) 2003-07-30 2011-10-12 里格尔药品股份有限公司 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
SG145749A1 (en) * 2003-08-15 2008-09-29 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
EP1799664A1 (de) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Heterozyklische derivate und ihre verwendung als stearoyl-coa-desaturase-inhibitoren
CA2580844A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
AR051090A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
JP4958785B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用
AR051026A1 (es) 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN101048410B (zh) 2004-10-29 2010-06-23 泰博特克药品有限公司 抑制hiv的双环嘧啶衍生物
US7563781B2 (en) 2005-01-14 2009-07-21 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
KR101312225B1 (ko) 2005-06-08 2013-09-26 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
EP1928437A2 (de) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese mittels muscarinrezeptormodulation
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (de) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
US7968536B2 (en) * 2007-06-29 2011-06-28 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as RAF kinase inhibitors
AR067354A1 (es) 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2798578C (en) 2010-05-21 2015-12-29 Chemilia Ab Novel pyrimidine derivatives
CA2830129C (en) 2011-03-24 2016-07-19 Chemilia Ab Novel pyrimidine derivatives
SG11201404234YA (en) * 2012-01-28 2014-08-28 Merck Patent Gmbh Triazolo[4,5-d]pyrimidine derivatives
WO2013131609A1 (en) 2012-03-07 2013-09-12 Merck Patent Gmbh Triazolopyrazine derivatives
CN105026398B (zh) * 2013-03-05 2018-05-18 默克专利股份公司 用于治疗疾病诸如癌症的三唑并[4,5-d]嘧啶衍生物
EP2964648B1 (de) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl oder heteroaryl)-2-(pyrazolyl, pyrrolidinyl oder cyclopentyl)aminopurin-derivate als antikrebsmittel
CN105164136B (zh) 2013-05-06 2017-12-22 默克专利股份公司 作为激酶抑制剂的大环化合物
CA2969587A1 (en) * 2014-12-05 2016-06-09 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
US11370793B2 (en) 2015-08-27 2022-06-28 Nantneuro, Llc Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
WO2017156527A1 (en) * 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease
JP2022520671A (ja) 2019-02-08 2022-03-31 フリークエンシー・セラピューティクス・インコーポレイテッド 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5962594A (ja) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５―ジ置換―トリアゾロピリミジン誘導体
US20020040031A1 (en) * 2000-07-07 2002-04-04 Glasky Michelle S. Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
US6737085B2 (en) * 2000-11-01 2004-05-18 Tokiwa Phytochemical Co., Ltd. Apocynum venetum extract for use as antidepressant
EP1347972A1 (de) * 2000-12-19 2003-10-01 Smithkline Beecham Plc PYRAZOLO-ç3,4-C!PYRIDINE ALS GSK3-INHIBITOREN
AU2004260738B2 (en) * 2003-07-16 2009-07-16 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors

Also Published As

Publication number Publication date
TW200524935A (en) 2005-08-01
DE602004008303T2 (de) 2008-05-08
IL173139A (en) 2010-04-29
US7560458B2 (en) 2009-07-14
KR20060120393A (ko) 2006-11-27
US20060205721A1 (en) 2006-09-14
ZA200600385B (en) 2007-05-30
JP2009514782A (ja) 2009-04-09
JO2460B1 (en) 2009-01-20
US20090036471A1 (en) 2009-02-05
PL1658292T3 (pl) 2008-01-31
BRPI0412596A (pt) 2006-09-19
EP1658292A1 (de) 2006-05-24
MXPA06000540A (es) 2006-03-30
PA8607001A1 (es) 2005-05-10
CN100404536C (zh) 2008-07-23
CN1823068A (zh) 2006-08-23
DE602004008303D1 (de) 2007-09-27
EA010109B1 (ru) 2008-06-30
EA200600258A1 (ru) 2006-06-30
CA2531333A1 (en) 2005-02-10
NZ545058A (en) 2008-05-30
AP2006003486A0 (en) 2006-02-28
IL173139A0 (en) 2006-06-11
DK1658292T3 (da) 2007-11-12
AR045698A1 (es) 2005-11-09
NO20060678L (no) 2006-02-10
PT1658292E (pt) 2007-10-25
WO2005012307A1 (en) 2005-02-10
ES2290754T3 (es) 2008-02-16
AU2004260738A1 (en) 2005-02-10
EP1658292B1 (de) 2007-08-15
AU2004260738B2 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
ATE370142T1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
ATE413404T1 (de) Triazolopyrimidin derivate als inhibitoren von glycogen synthase kinase-3
DE60315516D1 (de) Pyridazinon-derivate als cdk2-hemmer
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE402934T1 (de) Malonamidderivate als gamma-secretaseinhibitoren
ATE529421T1 (de) Chinolinderivate als phosphodiesterase-hemmer
ATE489387T1 (de) Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren
ATE416171T1 (de) 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
DE60321808D1 (de) Flavon derivate als inhibitoren von cyclin-abhängigen kinasen
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
NO20054880D0 (no) Azaspiroalkanderivater som inhibitorer av metallproeaser
DE602005025733D1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
NL1027811A1 (nl) Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.
IL183188A0 (en) Pyrrolidyl derivatives of heteroaromatic compounds as phosphodiesterase inhibitors
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE437876T1 (de) Hexahydropyridoisochinoline als dpp-iv- inhibitoren
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
DK1756064T3 (da) Pyrazolderivater, sammensætninger indeholdende sådanne forbindelser og anvendelsesmetoder
NO20045220L (no) Heterocykliske inhibitorer for kinaser
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren
ATE401893T1 (de) Thiophenepyrimidinone als 17-beta-hydroxysteroid dehydrogenase inhibitoren
IL178968A0 (en) Novel pyridazinone derivatives as inhibitors of cdk2

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1658292

Country of ref document: EP